2023-11-27 23:34:49
par Nancy Lapid
Obese or overweight adults lost more weight and shed pounds faster using Eli Lilly LLY.N’s Mounjaro than those taking the popular competing weight-loss drug, according to an analysis of medical records and other data. from Novo Nordisk NOVOb.CO.
One year after starting treatment, 42.3% of patients taking tirzepatide – the active ingredient in Mounjaro and Zepbound – had lost at least 15% of their weight, compared to 19.3% of patients taking semaglutide – the principle active Wegovy and Ozempic, according to the study published on medRxiv before being submitted for peer review.
After accounting for individual risk factors, patients taking Mounjaro were 76% more likely to lose at least 5% of their body weight, more than twice as likely to lose at least 10%, and more than three times more likely to lose at least 10% of their body weight. chance of losing at least 15%, compared to patients taking Ozempic, according to the report.
In the absence of randomized controlled trials comparing the two drugs, researchers used electronic medical records and pharmacy dispensing data to analyze weight loss trajectories in 9,193 patients receiving Mounjaro and the same number of patients closely matched receiving Ozempic. The average participant weighed 242 pounds (110 kg), and about half of them had type 2 diabetes.
After 3 months of treatment, patients on Mounjaro had lost an average of 2.3% more body weight than those on Ozempic, according to the study. After 6 months, the difference had increased to 4.3%, and after 12 months, the Mounjaro group had lost an average of 7.2% more weight.
Rates of gastrointestinal adverse events were similar between the groups, according to the researchers.
The researchers note that Ozempic and Mounjaro are both intended for people with type 2 diabetes, but that half of the study participants used the drugs only for weight loss, which may have impacted the results .
In an emailed statement, Novo Nordisk said: “The doses of semaglutide evaluated in this analysis have not been studied for chronic weight management, and there are no head-to-head trials which have been (and) reported which evaluate Wegovy and tirzepatide.”
An Eli Lilly spokesperson said the company does not promote or encourage off-label use of any of its drugs, although its drug is now approved for weight loss.
A trial is underway to compare the weight loss formulations of the two drugs injected into patients who are overweight or obese but do not suffer from type 2 diabetes. Results are not expected before 2025.
Meanwhile, the Novo spokesperson pointed out that the study report mentions: “This preprint reports new research that has not been peer-reviewed and should not be used to guide practice clinical
1701135058
#Lillys #Mounjaro #greater #faster #weight #loss #Novos #obesity #drug #data #analysis #shows